Evonik Industries/€EVK

Evonik falls 3.5% after Ifo survey showed German chemical industry sentiment plunged to lowest in over 30 years on weak orders and intensifying competition.
17 hours agoLightyear AI
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX

About Evonik Industries

Evonik Industries AG, a German multinational, specializes in producing specialty chemicals, primarily focusing on consumer goods, animal nutrition, and pharmaceuticals. Founded in 1873, the company operates globally and is structured into multiple segments including Specialty Additives, Nutrition & Care, and Smart Materials among others. As a publicly traded entity, it is listed on the Frankfurt Stock Exchange under the ticker EVK.

Ticker

€EVK
Sector

Primary listing

XETRA

Employees

31,297
Headquarters
Website

EVK Metrics

BasicAdvanced
€6.6B
69.30
€0.20
0.73
€1.17
8.26%

What the Analysts think about EVK

Analyst ratings (Buy, Hold, Sell) for Evonik Industries stock.

Bulls say / Bears say

Evonik’s first-quarter 2025 adjusted EBITDA climbed 7 percent to €560 million, surpassing analyst expectations of €543 million, and grew its margin to 14.8 percent, driven by strong performance in Nutrition & Care and tight cost management (Reuters)
At its May 2025 Capital Markets Day, Evonik introduced a strategic framework aimed at adding €1 billion to core EBITDA by 2027, split equally between internal growth and cost savings, in order to achieve an 11 percent return on capital employed (Reuters)
Investor sentiment remains positive, with Evonik’s share price nearly 20 percent higher year-to-date following its resilient first-quarter results and the confirmation of guidance (Reuters)
Evonik lowered its 2025 core profit guidance to around €1.9 billion, below its previous €2.0–2.3 billion range and the median analyst estimate of €1.96 billion, citing ongoing weak demand. This marks the second downward revision in recent months (Reuters)
In the second quarter of 2025, Evonik’s core profit dropped 12 percent year-over-year to €509 million, missing the analyst consensus of €511 million and pointing to continued demand challenges across its segments (Reuters)
The abrupt resignation of CFO Maike Schuh after the profit-guidance cut raises concerns about execution risk, especially as the company undertakes its largest-ever restructuring (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 11 Nov 2025.

EVK Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

EVK Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €EVK

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs